Nuveen Asset Management, LLC Black Diamond Therapeutics, Inc. Transaction History
Nuveen Asset Management, LLC
- $345 Billion
- Q3 2024
A detailed history of Nuveen Asset Management, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 178,733 shares of BDTX stock, worth $368,189. This represents 0.0% of its overall portfolio holdings.
Number of Shares
178,733
Previous 122,003
46.5%
Holding current value
$368,189
Previous $568,000
36.8%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BDTX
# of Institutions
118Shares Held
48.9MCall Options Held
1.84MPut Options Held
1.93M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$22.1 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$17.5 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$10.4 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$9.16 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$6.63 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $74.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...